NextFin News - Anduril Industries is letting employees sell shares at $94.80 apiece in a roughly $1.3 billion tender offer that values the defense-technology startup at about $90 billion — tripling its worth in 16 months and landing less than five months after a $5 billion funding round priced the company at $61 billion. The move carries a sharper edge than a routine liquidity event: in July, Chief Executive Brian Schimpf told investors the market is "not particularly rational on the pricing right now" and that many defense-tech companies are "dangerously leading into overvalued territory in a way that could backfire."
The tender, which opened on Oct. 13 and runs through Nov. 9, is open to current and former employees across 16 countries. It does not raise new capital for Anduril and does not dilute existing holders; it simply lets insiders convert paper wealth into cash at a price the company itself is setting. That price — $94.80 a share — implies a valuation roughly 48% above the $61 billion tag from the Series H round led by Thrive Capital and Andreessen Horowitz, which closed in May. Yet it sits at a discount to what shares are changing hands for on secondary platforms, where indicative prices have been quoted as high as $132.12 per share, implying a valuation near $117 billion.
Here is the tension worth resolving: why would a company whose own chief executive has publicly warned about irrational pricing agree to a near-50% valuation step-up in five months, while pricing its insider tender below the open secondary market? The answer separates the structural shift reshaping defense spending from the cyclical wave of multiple expansion riding on top of it — and it tells investors what to watch before the next leg of the defense-tech boom either proves itself or rolls over.
The Tender in Numbers: A Liquidity Event, Not a Fundraising Round
The mechanics matter because they are easily misread. A tender offer of this kind is secondary: shares change hands between employees and buyers — typically venture-capital firms, family offices, and hedge funds that specialize in late-stage private companies — and no proceeds go to Anduril's balance sheet. The company is not selling stock, and it is not issuing new shares. That distinguishes this event from the $5 billion primary raise in May, which put fresh capital into the business to fund factories, research, and hiring.
The terms, as reported by people familiar with the matter, are specific: $94.80 per share, a total size capped at about $1.3 billion, and a closing date of Nov. 9. Open to current and former employees in 16 countries, the offer is a standard retention-and-reward tool for a private company that has grown to roughly 7,000 people — nearly double the headcount of a year earlier. For employees sitting on years of unvested or illiquid equity, a company-sponsored tender is often the only clean exit available before an initial public offering.
But the valuation math is what draws attention. Anduril's price history reads like a compounding curve:
- December 2022: $8.5 billion
- August 2024 (Series F): $14 billion
- June 2025 (Series G, $2.5 billion raise): $30.5 billion
- May 2026 (Series H, $5 billion raise): $61 billion
- October 2026 (tender): approximately $90 billion
That is a 10.6-fold increase in valuation in under four years. The last leg — from $61 billion to $90 billion — took roughly five months and represents a 48% gain. For comparison, the jump from $30.5 billion to $61 billion, which took about 11 months, was also a doubling. The cadence is accelerating even as the base gets larger, which is precisely the pattern that makes valuation discipline harder to maintain.
The Fundamentals Underneath the Multiple
Every valuation is a claim about the future, and Anduril's future is being underwritten by revenue growth that is, by any measure, exceptional. The company generated approximately $2.2 billion in revenue in 2025, up from about $1 billion in 2024 — a 120% increase. For 2026, it is guiding to roughly $4.3 billion, which would nearly double revenue again. That trajectory is what allows supporters to argue that today's price is tomorrow's bargain: a $90 billion valuation on $4.3 billion of sales is a price-to-sales multiple of about 21 times forward revenue.
There is, however, a cost to that growth. Anduril is forecasting an operating loss of approximately $1.2 billion for 2026 — a wider dollar loss than its entire annual revenue was just two years ago. The company does not expect to turn a profit until around 2030, according to reporting on its internal projections. In other words, the business is losing roughly 28 cents on every dollar it expects to book this year, and it is asking the market to underwrite those losses for at least four more years.
The losses are not an accident; they are the bill for a deliberate strategy. Anduril is building physical industrial capacity at a pace few software companies ever attempt. Its Arsenal-1 factory in Ohio — a roughly $900 million project expected to eventually employ 4,000 workers — began producing Fury drones and other hardware in 2026. The company has also opened a solid-rocket-motor plant in McHenry, Mississippi, a $75 million site that employs more than 100 workers and aims to produce 6,000 tactical motors annually by the end of 2026. These are capital-intensive bets that the future of defense procurement belongs to companies that can both design autonomy software and manufacture hardware at scale.
"We define a successful IPO as our investors got a good return three years from actually going out," Schimpf said at the Allen & Co. Sun Valley Conference in July. "A bad time to do that is in the middle of a hype cycle. So we're not in a rush to go out."
That quote, delivered just months before this tender, is the lens through which the $90 billion figure should be read. Schimpf went further, warning that "a lot of companies are dangerously leading into overvalued territory in a way that could backfire," and adding, "I'm not sure that the market is particularly rational on the pricing right now." He said this while sitting atop one of the most richly valued private technology companies in the world — a company whose valuation has just been marked up another 48%.
Structural Shift, Cyclical Wave: Separating the Two Forces
The defense-technology sector is in the middle of something that looks structural. Global defense budgets are rising toward $1.5 trillion. Washington has framed reindustrialization of the defense base as a strategic imperative, and defense assessments cited in Anduril's own investor communications identify 2027 as a "window of maximum danger" with China — a period when Beijing may judge its military capabilities ready for a decisive test. That framing creates a multi-year procurement tail that is not dependent on any single election cycle or quarterly earnings print. Anduril's products — autonomous drones, counter-drone systems, undersea vehicles, and the Lattice AI battle-management software that ties them together — sit directly in the path of that spending.
This is the structural leg of the argument, and it is real. A regime change in defense procurement — from long-cycle, prime-contractor-led programs to faster, software-native, attritable systems — does not revert on its own. Once a military integrates autonomous systems into its doctrine, it does not unwind that integration. Anduril's vertically integrated stack, combining software and hardware, is a durable competitive position if the company can execute.
But riding on top of that structural shift is a cyclical wave of multiple expansion that is far less durable. A valuation that has risen 10.6 times in under four years, and 48% in five months, while the company loses $1.2 billion a year, is being carried by investor sentiment as much as by fundamentals. Cyclical forces are mean-reverting by definition: liquidity conditions tighten, risk appetite fades, and multiples compress back toward historical norms. The structural argument explains why defense technology deserves a higher multiple than it had a decade ago; it does not explain why every defense-technology name should trade at any price investors are willing to pay today.
The distinction matters because it determines the conclusion. If the move is structural, the $90 billion mark is a waypoint on a long climb. If the move is cyclical, the tender — priced below the frothy secondary market but well above the last primary round — is a company quietly taking a more conservative view of its own worth than the crowd.
The Second-Order Question: What a Below-Market Tender Price Is Really Saying
The first-order reading of this event is simple: employees get liquidity, and the company's valuation goes up. The second-order question is why the tender price of $94.80 sits roughly 28% below the $132.12 per share indicative price quoted on secondary platforms, and about 19% below the roughly $116.68 per share indication tracked by private-market data providers — levels that imply valuations of $117 billion and $100 billion respectively.
A company-sponsored tender is not priced by the market; it is set by the company. Anduril could have priced the offer at or near the secondary indication and cleared it instantly. Instead it chose $94.80. There are benign explanations: tenders are discounted to compensate buyers for guaranteed settlement, to avoid adverse selection where only the most motivated sellers participate, and to leave room for the buyers who are taking concentrated, illiquid positions. A 20% to 30% discount to a noisy secondary print is not abnormal for a tender of this size.
But the third-order implication is the one that deserves attention. If the people with the best information about Anduril's trajectory — its management and its largest shareholders — believed the secondary market's $117 billion implied valuation was conservative, the natural move would be to price the tender closer to it, or to skip the tender entirely and wait for a public listing. Choosing a price 28% below the secondary market, while publicly describing that market as irrational, is a quiet signal that the insiders are willing to monetize at $90 billion and are in no hurry to chase the last 20%.
That does not mean the stock is headed lower. It means the asymmetry has shifted. At $90 billion, the company is asking new buyers to underwrite four more years of nine-figure losses on the promise that revenue doubles again and profitability arrives around 2030. At $117 billion, the same promise buys considerably less margin of safety.
The Counter-Thesis: This Is Just Routine Liquidity
The strongest argument against reading anything ominous into this tender is also the simplest: it is routine. A private company with 7,000 employees, many of whom have been with the company for years, needs to provide liquidity or risk losing talent to competitors that can. Company-sponsored tenders are standard practice for late-stage startups, and the discount to secondary prices reflects the mechanics of a guaranteed, company-run process — not a valuation judgment. Anduril itself is not selling a single share; no new capital is being raised; nothing about the company's operating plan has changed.
There is force in that view. Tenders are priced conservatively by design, and a company that wanted to signal distress would not be marking its valuation up 48% at all. The counter-thesis also has a named authority behind it: founder Palmer Luckey has said he "definitely" aims to take the company public, and management has repeatedly framed its capital raising as preparation for long-term scale, not an exit.
But the counter-thesis does not fully hold, for two reasons. First, routine tenders typically track the most recent primary round price; this one is marked up 48% above it, which is not conservative pricing — it is aggressive pricing dressed in conservative clothing. Second, the timing sits awkwardly against the CEO's own July warning about overvaluation. A management team that genuinely believed the market was underpricing its shares would not be facilitating a $1.3 billion exit for insiders at a discount to the secondary market; it would be buying shares back.
The falsifying signal is specific and observable. If Anduril reports 2026 revenue at or above its $4.3 billion guidance while operating losses narrow toward the 2030 profitability target, the $90 billion valuation is defensible and the tender will look like a routine liquidity event in retrospect. If revenue misses guidance or losses exceed the $1.2 billion forecast while the secondary price remains above $120 per share, the valuation will have been detached from fundamentals — and the tender will have been the moment insiders chose certainty over conviction.
What to Watch: Three Time Horizons
Short term (through Nov. 9): The tender closes, and the market will watch how much of the $1.3 billion cap is actually taken up. Heavy participation would confirm pent-up employee demand for liquidity; light participation could suggest employees are holding out for a higher public-market price. Secondary prices on private-market platforms will be the real-time referendum on whether $90 billion holds.
Medium term (2026–2027): Revenue delivery is the whole ballgame. The $4.3 billion guide for 2026 is the number that either validates the multiple or breaks it. So is the ramp at Arsenal-1: a $900 million factory only creates value if it converts capital into deployable systems on schedule. The 2027 "window of maximum danger" narrative around China will either drive procurement urgency or fade into background noise.
Long term (2028–2030): The path to profitability. A company that loses $1.2 billion a year cannot compound at this pace indefinitely. The question is whether manufacturing scale produces the margin expansion that turns $4.3 billion of revenue into sustainable profits by 2030, or whether defense primes and new entrants compete the excess returns away.
Three scenarios frame the range:
- Base case: Revenue lands near $4.3 billion in 2026, losses persist but remain within guidance, and the valuation consolidates in the $80 billion to $100 billion range. An IPO remains unlikely before 2027, consistent with Schimpf's stated reluctance to list "in the middle of a hype cycle."
- Upside case: Revenue beats guidance, losses narrow ahead of schedule, and Anduril lists at a valuation above $100 billion in a receptive window. The $90 billion tender then looks like a bargain entry point.
- Downside case: Revenue misses, losses exceed $1.2 billion, and private-market marks roll back toward the $61 billion Series H level. In that world, the tender becomes the high-water mark for this cycle.
The defense-technology boom is built on a premise that is hard to argue with: the world is becoming more dangerous, and technology will determine who wins. Anduril is one of the best-positioned companies in that trade. But the tender at $90 billion is a reminder that even the strongest structural story has a price — and that the people closest to the numbers are sometimes the first to test where that price actually is.
The bottom line: Anduril's tender is less a verdict on the company than a mirror held up to the defense-tech boom. The people with the best information are cashing out at $90 billion while their own CEO warns the market is not being rational. One of those two signals is right — and by 2027, revenue will say which.
Explore more exclusive insights at nextfin.ai.
